Related Experiment Video
Updated: Dec 29, 2025
10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
2.2K
Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation.
1Department of Pharmacology, Chonnam National University Medical School, Hwasun, Korea.
Chonnam Medical Journal
|February 6, 2020
Summary
Cancer cells evade immune detection, but Chimeric Antigen Receptor (CAR) T-cell therapy offers a promising approach. This immunotherapy harnesses engineered T cells to target and eliminate cancer cells, showcasing significant therapeutic potential.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cancer is a major cause of mortality despite advanced treatments.
- Tumors can evade immune surveillance even in immunocompetent individuals.
- Cancer cells employ immune evasion strategies, like expressing programmed death (PD) ligand 1.
Purpose of the Study:
- To review the current achievements of CAR T-cell therapy in oncology.
- To discuss the future therapeutic potential of CAR T-cell treatments.
Main Methods:
- Review of existing literature on CAR T-cell therapy.
- Analysis of CAR T-cell mechanisms in targeting cancer cells.
- Discussion of engineered approaches for CAR T-cell activation.
Main Results:
- CAR T-cell therapy demonstrates success in targeting cancer cells.
- Engineered CAR T cells offer specific activation pathways.
- CAR T-cell therapy is adaptable for various diseases.
Conclusions:
- CAR T-cell therapy represents a significant advancement in cancer treatment.
- Further research into CAR T-cell potential could revolutionize oncology.
- This immunotherapy approach holds promise for diverse clinical applications.
